SBFM · Sunshine Biopharma, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.09M | - | $9.42M | $9.41M | $8.90M | - | $8.44M | $9.30M | $7.54M | - |
| Cost of Revenue | $5.91M | - | $6.34M | $5.99M | $6.17M | - | $5.57M | $6.95M | $5.19M | - |
| Gross Profit | $2.18M | - | $3.07M | $3.42M | $2.73M | - | $2.87M | $2.36M | $2.35M | - |
| R&D | $31.7K | - | $119.3K | $196.2K | $215.3K | - | $126.4K | $436.2K | $222.0K | - |
| SG&A | $3.58M | - | $4.16M | $5.48M | $4.03M | - | $3.97M | $3.62M | $3.70M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $76.9K | - | $95.8K | $72.5K | $42.6K | - | $64.6K | $50.9K | $42.6K | - |
| Operating Income | ($1.40M) | - | ($1.09M) | ($2.05M) | ($1.30M) | - | ($1.11M) | ($1.27M) | ($1.35M) | - |
| Interest Expense | - | - | $0 | $0 | $49.2K | - | $0 | $3.3K | $49.2K | - |
| Income Tax | $0 | - | ($137.4K) | ($209.2K) | ($40.2K) | - | $215.2K | ($343.7K) | $22.4K | - |
| Net Income | ($1.24M) | - | ($883.8K) | ($1.77M) | ($1.18M) | - | ($1.20M) | ($494.3K) | ($1.28M) | - |
| EPS - Basic | ($2.50) | - | ($1.90) | ($3.90) | ($4.40) | - | ($9.40) | ($99.40) | ($400.00) | - |
| EPS - Diluted | - | - | - | ($434.80) | ($4.40) | - | - | - | ($400.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.91M | $9.12M | $9.31M | $10.31M | $8.12M | $9.69M | $12.21M | $11.51M | $17.43M | $16.29M |
| Accounts Receivable | $4.01M | $3.46M | $4.16M | $3.59M | $3.45M | $3.87M | $3.22M | $3.97M | $2.83M | $2.55M |
| Inventory | $13.17M | $13.47M | $14.06M | $13.02M | $11.86M | $11.28M | $9.82M | $8.49M | $7.70M | $5.73M |
| Accounts Payable | $5.10M | $5.66M | $6.14M | $4.80M | $5.02M | $5.54M | $4.16M | $4.93M | $3.62M | $2.59M |
| Current Assets | $24.78M | $26.85M | $27.97M | $27.85M | $24.48M | $25.97M | $25.98M | $25.75M | $28.83M | $24.89M |
| Total Assets | $27.93M | $30.08M | $31.49M | $31.97M | $29.19M | $30.56M | $30.06M | $29.30M | $31.90M | $27.35M |
| Current Liabilities | $5.88M | $6.44M | $6.65M | $5.57M | $5.76M | $6.31M | $4.53M | $5.30M | $6.53M | $5.55M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.41M | $7.04M | $7.29M | $6.28M | $6.48M | $7.06M | $5.02M | $5.81M | $7.08M | $6.14M |
| Stockholders' Equity | $21.52M | $23.04M | $24.20M | $25.68M | $22.70M | $23.50M | $25.04M | $23.49M | $24.82M | $21.21M |
| Retained Earnings | ($76.26M) | ($75.02M) | ($72.87M) | ($71.99M) | ($70.22M) | ($69.04M) | ($66.88M) | ($65.68M) | ($65.19M) | ($63.91M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.07M) | - | - | - | ($1.71M) | - | - | - | ($3.19M) | - |
| Investing Cash Flow | ($104.5K) | - | - | - | ($176.0K) | - | - | - | ($668.7K) | - |
| Financing Cash Flow | $0 | - | - | - | $338.1K | - | - | - | $5.40M | - |
| CapEx | $5.1K | - | - | - | $62.9K | - | - | - | - | - |
| Free Cash Flow | ($2.08M) | - | - | - | ($1.78M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 27.0% | - | 32.6% | 36.4% | 30.7% | - | 34.0% | 25.3% | 31.2% | - |
| Operating margin | -17.3% | - | -11.5% | -21.8% | -14.6% | - | -13.1% | -13.6% | -17.9% | - |
| EBITDA margin | -16.3% | - | -10.5% | -21.1% | -14.1% | - | -12.3% | -13.1% | -17.3% | - |
| Net margin | -15.4% | - | -9.4% | -18.8% | -13.3% | - | -14.2% | -5.3% | -17.0% | - |
| Free cash flow margin | -25.7% | - | - | - | -20.0% | - | - | - | - | - |
| FCF / Net income | 1.67 | - | - | - | 1.51 | - | - | - | - | - |
| R&D / Revenue | 0.4% | - | 1.3% | 2.1% | 2.4% | - | 1.5% | 4.7% | 2.9% | - |
| SG&A / Revenue | 44.2% | - | 44.2% | 58.2% | 45.2% | - | 47.1% | 39.0% | 49.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.5% | - | -2.8% | -5.5% | -4.0% | - | -4.0% | -1.7% | -4.0% | - |
| Return on equity | -5.8% | - | -3.7% | -6.9% | -5.2% | - | -4.8% | -2.1% | -5.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.22 | 4.17 | 4.20 | 5.00 | 4.25 | 4.11 | 5.74 | 4.86 | 4.41 | 4.48 |
| Quick ratio | 1.98 | 2.08 | 2.09 | 2.66 | 2.19 | 2.33 | 3.57 | 3.26 | 3.23 | 3.45 |
| Cash ratio | 1.18 | 1.42 | 1.40 | 1.85 | 1.41 | 1.53 | 2.70 | 2.17 | 2.67 | 2.93 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -26.3x | - | - | -380.7x | -27.5x | - |
| Equity multiplier | 1.30 | 1.31 | 1.30 | 1.24 | 1.29 | 1.30 | 1.20 | 1.25 | 1.29 | 1.29 |
| Liabilities / Assets | 0.23 | 0.23 | 0.23 | 0.20 | 0.22 | 0.23 | 0.17 | 0.20 | 0.22 | 0.22 |
| Efficiency | ||||||||||
| Asset turnover | 0.29 | - | 0.30 | 0.29 | 0.30 | - | 0.28 | 0.32 | 0.24 | - |
| Inventory turnover | 0.45 | - | 0.45 | 0.46 | 0.52 | - | 0.57 | 0.82 | 0.67 | - |
| Days sales outstanding | 181d | - | 161d | 139d | 141d | - | 139d | 156d | 137d | - |
| Days inventory outstanding | 814d | - | 809d | 794d | 701d | - | 644d | 446d | 542d | - |
| Days payable outstanding | 315d | - | 353d | 292d | 297d | - | 272d | 259d | 254d | - |
| Cash conversion cycle | 679d | - | 617d | 640d | 545d | - | 510d | 343d | 424d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 0.2x | 0.2x | - | 0.2x | 0.0x | 3.2x | - |
| P / S | - | - | - | 0.6x | 0.6x | - | 0.5x | 0.0x | 10.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.1% | - | 11.6% | 1.2% | 18.0% | - | 41.6% | 67.3% | 54.1% | - |
| Revenue CAGR (3y) | 18.2% | - | 313.9% | 297.1% | 317.1% | - | 451.2% | 460.4% | 473.1% | - |
| Revenue CAGR (5y) | 189.1% | - | 253.1% | 262.0% | 280.9% | - | 309.5% | 398.1% | 141.8% | - |
| Gross profit growth (YoY) | -20.1% | - | 7.2% | 45.3% | 16.0% | - | 44.0% | 20.7% | 28.8% | - |
| Operating income growth (YoY) | -7.7% | - | 1.8% | -62.0% | 4.1% | - | -41.9% | -28.2% | 26.2% | - |
| Net income growth (YoY) | -5.4% | - | 26.2% | -258.3% | 8.1% | - | -83.9% | 45.2% | 24.6% | - |
| EPS growth (YoY) | - | - | - | - | 98.9% | - | - | - | -499900.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -16.9% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -5.2% | -2.0% | -3.4% | 9.3% | -8.5% | 10.8% | 14.0% | 1.6% | 27.7% | -1.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sunshine Biopharma against the 5 most active filers in the same SIC group.